| Literature DB >> 27693859 |
Daniel J Tyrrell1, Manish S Bharadwaj1, Matthew J Jorgensen2, Thomas C Register2, Anthony J A Molina3.
Abstract
Blood based bioenergetic profiling strategies are emerging as potential reporters of systemic mitochondrial function; however, the extent to which these measures reflect the bioenergetic capacity of other tissues is not known. The premise of this work is that highly metabolically active tissues, such as skeletal and cardiac muscle, are susceptible to differences in systemic bioenergetic capacity. Therefore, we tested whether the respiratory capacity of blood cells, monocytes and platelets, are related to contemporaneous respirometric assessments of skeletal and cardiac muscle mitochondria. 18 female vervet/African green monkeys (Chlorocebus aethiops sabaeus) of varying age and metabolic status were examined for this study. Monocyte and platelet maximal capacity correlated with maximal oxidative phosphorylation capacity of permeabilized skeletal muscle (R=0.75, 95% confidence interval [CI]: 0.38-0.97; R=0.51, 95%CI: 0.05-0.81; respectively), isolated skeletal muscle mitochondrial respiratory control ratio (RCR; R=0.70, 95%CI: 0.35-0.89; R=0.64, 95%CI: 0.23-0.98; respectively), and isolated cardiac muscle mitochondrial RCR (R=0.55, 95%CI: 0.22-0.86; R=0.58, 95%CI: 0.22-0.85; respectively). These results suggest that blood based bioenergetic profiling may be used to report on the bioenergetic capacity of muscle tissues. Blood cell respirometry represents an attractive alternative to tissue based assessments of mitochondrial function in human studies based on ease of access and the minimal participant burden required by these measures.Entities:
Keywords: Bioenergetics; Blood cells; Cellular respiration; Mitochondria; Muscle
Mesh:
Substances:
Year: 2016 PMID: 27693859 PMCID: PMC5045569 DOI: 10.1016/j.redox.2016.09.009
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Baseline characteristics of non-human primate subjects enrolled in this study.
| Age (years) | 16.6 | 6.1 | 8.4–23.7 | 18 | |
| Weight (kg) | 4.9 | 1.0 | 3.3–6.9 | 18 | |
| BMI (kg/m2) | 60.7 | 10.5 | 44.6–82.3 | 18 | |
| Glucose (mg/dL) | 127.7 | 70.6 | 73.0–319.0 | 18 | |
| Insulin (mIU/L) | 23.7 | 26.7 | 4.6–114.6 | 18 | |
| HOMA-IR | 6.9 | 7.1 | 1.0–27.2 | 18 | |
BMI=body mass index, HOMA-IR=homeostatic model of insulin resistance, SD=standard deviation.
BMI was estimated using trunk length measured from the suprasternal notch to the pubic symphysis.
Fig. 1Representative bioenergetic profiles from CD14+ monocytes, platelets, skeletal muscle isolated mitochondria, cardiac isolated mitochondria, and permeabilized skeletal muscle fibers from one animal. Respiration is measured as oxygen consumption rate (pmol/min/250,000 cells [monocytes], pmol/min/mg protein [platelets], pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]), and pmol/min/mg dry weight [permeabilized fibers]. In isolated mitochondrial preparations, complex II (CII) respiration was measured using succinate and rotenone as substrates. Ama=antimycin-A, c=cytochrome c, D=adenosine diphosphate, F=carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone, G=glutamate, M=malate, O=oligomycin, P=pyruvate, R=rotenone, S=succinate, U=uncoupler (FCCP).
Baseline bioenergetic characteristics of non-human primate subjects enrolled in this study.
| Platelet basal | 299.0 | 98.8 | 162.2–435.6 | 17 | |
| Platelet oligomycin OCR | 98.3 | 26.4 | 54.4–140.4 | 15 | |
| Platelet MAX | 438.1 | 159.8 | 209.3–699.5 | 17 | |
| Platelet non-mitochondrial OCR | 84.4 | 23.3 | 36.1–124.4 | 17 | |
| Platelet reserve capacity | 139.1 | 78.5 | 27.4–263.9 | 17 | |
| Platelet ATP OCR | 198.4 | 77.9 | 76.8–304.0 | 15 | |
| Platelet leak OCR | 12.2 | 13.5 | −7.2 to 39.1 | 15 | |
| Monocyte basal | 79.6 | 37.3 | 39.3–158.8 | 11 | |
| Monocyte oligomycin OCR | 25.2 | 9.4 | 13.7–37.3 | 9 | |
| Monocyte MAX | 116.2 | 54.9 | 50.6–225.3 | 11 | |
| Monocyte non-mitochondrial OCR | 19.0 | 12.7 | −8.8 to 37.9 | 11 | |
| Monocyte reserve capacity | 36.6 | 19.6 | 10.7–66.4 | 11 | |
| Monocyte ATP OCR | 48.8 | 24.8 | 19.6–86.5 | 9 | |
| Monocyte leak OCR | 4.7 | 10.6 | −20.6 to 13.9 | 9 | |
| Permeabilized fiber basal | 34.8 | 9.2 | 23.4–57.8 | 17 | |
| Permeabilized fiber leak OCR | 33.6 | 12.2 | 21.0–67.1 | 17 | |
| Permeabilized fiber complex I OXPHOS | 93.9 | 22.7 | 60.1–145.7 | 17 | |
| Permeabilized fiber complex I+II OXPHOS | 133.3 | 34.4 | 68.0–197.6 | 17 | |
| Permeabilized fiber cytochrome C membrane integrity | 132.7 | 35.8 | 63.5–200.3 | 17 | |
| Permeabilized fiber MAX | 157.4 | 33.4 | 116.8–215.7 | 17 | |
| Permeabilized fiber non-mitochondrial OCR | 12.0 | 3.8 | 5.1–20.1 | 17 | |
| Left vastus isolated mitochondria CII oligomycin OCR | 117.4 | 50.8 | 43.0–240.5 | 16 | |
| Left vastus isolated mitochondria CII state 3 | 581.4 | 247.9 | 162.1–1082.1 | 16 | |
| Left vastus isolated mitochondria CII MAX | 601.2 | 292.1 | 156.6–1062.0 | 16 | |
| Left vastus isolated mitochondria CII RCR-A | 5.1 | 1.4 | 2.6–8.4 | 16 | |
| Left vastus isolated mitochondria CII RCR-F | 5.1 | 1.5 | 2.5–7.5 | 16 | |
| Cardiac isolated mitochondria CII oligomycin OCR | 162.6 | 68.2 | 47.2–268.5 | 16 | |
| Cardiac isolated mitochondria CII state 3 | 633.4 | 213.9 | 171.9–928.4 | 16 | |
| Cardiac isolated mitochondria CII MAX | 669.1 | 225.7 | 265.6–1052.5 | 16 | |
| Cardiac isolated mitochondria CII RCR-A | 4.1 | 1.0 | 2.8–6.8 | 16 | |
| Cardiac isolated mitochondria CII RCR-F | 4.4 | 1.1 | 2.8–7.2 | 16 | |
ATP=adenosine triphosphate, CII=complex 2, FCCP=Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone, MAX=FCCP-linked respiration, OCR=oxygen consumption rate, OXPHOS=oxidative phosphorylation capacity, RCR=respiratory control ratio.
Respiration is measured as oxygen consumption rate (pmol/min/mg protein [platelets], pmol/min/250,000 cells [monocytes], pmol/min/mg dry weight [permeabilized fibers], pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]).
In blood cell respiration, Reserve capacity is calculated as the difference between MAX and Basal respiration and Leak is calculated as the difference between Oligo and A/R respiration.
RCRs are calculated as ADP-stimulated State 3 respiration divided by oligomycin-linked respiration (RCR-A) and by MAX respiration divided by oligomycin-linked respiration (RCR-F).
In permeabilized muscle fiber preparations, basal respiration was measured with no added substrates, leak was measured with malate added, complex I OXPHOS capacity was measured using pyruvate, glutamate, and malate with a saturating amount of ADP. Complex I+II OXPHOS capacity was measured using complex I substrates with succinate added. Cytochrome C Membrane Integrity was measured with Complex I+II substrates with cytochrome c added. MAX respiration was measured using complex I+II substrates with FCCP titrations added. Non-mitochondrial respiration was measured with MAX substrates with antimycin-A and rotenone substrates added.
In isolated mitochondrial preparations, CII respiration was measured using succinate and rotenone as substrates and using ADP, oligomycin, and FCCP injections to measure State 3, oligomycin, and MAX, respectively.
Relationship between monocyte bioenergetics with skeletal and cardiac muscle bioenergetics. Pearson correlations and 95% confidence intervals of monocyte respiratory parameters with bioenergetics from permeabilized skeletal muscle fibers and isolated mitochondria from vastus lateralis and cardiac tissue.
| Basal | −0.43 (−0.74 to 0.03) | −0.42 (−0.74 to 0.03) | −0.33 (−0.65 to 0.17) |
| Complex I OXPHOS | |||
| Complex I+II OXPHOS | |||
| MAX | 0.09 (−0.51 to 0.73) | −0.01 (−0.59 to 0.70) | −0.20 (−0.67 to 0.57) |
| State 3 | −0.24 (−0.73 to 0.55) | −0.24 (−0.79 to 0.63) | −0.23 (−0.86 to 0.67) |
| MAX | −0.20 (−0.73 to 0.55) | −0.18 (−0.76 to 0.56) | −0.13 (−0.79 to 0.62) |
| RCR-A | |||
| RCR-F | |||
| State 3 | 0.06 (−0.36 to 0.68) | 0.09 (−0.40 to 0.64) | 0.14 (−0.45 to 0.64) |
| MAX | 0.16 (−0.29 to 0.85) | 0.19 (−0.32 to 0.82) | 0.22 (−0.43 to 0.74) |
| RCR-A | |||
| RCR-F | 0.52 (−0.21 to 0.98) | 0.50 (−0.18 to 0.96) | 0.41 (−0.11 to 0.89) |
CII=complex 2, FCCP=carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, MAX=FCCP-linked respiration, OXPHOS=oxidative phosphorylation capacity, RCR=respiratory control ratio. Bold type = p-value ≤ 0.05.
Respiration is measured as oxygen consumption rate (pmol/min/250,000 cells [monocytes], pmol/min/mg dry weight [permeabilized fibers], pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]).
Reserve capacity is calculated as the difference between MAX and Basal respiration.
RCRs are calculated as ADP-stimulated State 3 respiration divided by oligomycin-linked respiration (RCR-A) and by MAX respiration divided by oligomycin-linked respiration (RCR-F).
In permeabilized muscle fiber preparations, basal respiration was measured with no added substrates, leak was measured with malate added, complex I OXPHOS capacity was measured using pyruvate, glutamate, and malate with a saturating amount of ADP. Complex I+II OXPHOS capacity was measured using complex I substrates with succinate added. MAX respiration was measured using complex I+II substrates with FCCP titrations added. Non-mitochondrial respiration was measured with MAX substrates with antimycin-A and rotenone substrates added.
In isolated mitochondrial preparations, CII respiration was measured using succinate and rotenone as substrates and using ADP, oligomycin, and FCCP injections to measure State 3, oligomycin, and MAX respiration, respectively.
N=11–12.
Fig. 2Associations among CD14+ monocyte bioenergetic parameters with skeletal and cardiac muscle bioenergetics. Regressions between monocyte maximal uncoupled respiration and reserve capacity with respiratory control ratio and maximal uncoupled respiration from isolated mitochondria from skeletal and cardiac muscle as well as maximal oxidative phosphorylation capacity and maximal uncoupled respiration from permeabilized skeletal muscle fibers. Pearson's correlations and p-values for each association are shown.
Relationship between platelet bioenergetics with skeletal and cardiac muscle bioenergetics. Pearson correlations and 95% confidence intervals of platelet respiratory parameters with bioenergetics from permeabilized skeletal muscle fibers and isolated mitochondria from vastus lateralis and cardiac tissue.
| Basal | −0.06 (−0.53 to 0.42) | 0.10 (−0.56 to 0.57) | 0.27 (−0.61 to 0.74) |
| Complex I OXPHOS | 0.19 (−0.39 to 0.67) | 0.34 (−0.21 to 0.72) | 0.45 (−0.04 to 0.79) |
| Complex I+II OXPHOS | 0.34 (−0.25 to 0.81) | ||
| MAX | 0.26 (−0.29 to 0.81) | ||
| State 3 | 0.05 (−0.46 to 0.64) | 0.32 (−0.06 to 0.64) | |
| MAX | 0.12 (−0.46 to 0.72) | 0.36 (−0.07 to 0.70) | |
| RCR-A | 0.40 (−0.24 to 0.87) | ||
| RCR-F | 0.49 (−0.18 to 0.93) | ||
| State 3 | −0.26 (−0.66 to 0.29) | −0.08 (−0.53 to 0.47) | 0.18 (−0.31 to 0.68) |
| MAX | −0.16 (−0.61 to 0.41) | 0.01 (−0.48 to 0.54) | 0.22 (−0.31 to 0.70) |
| RCR-A | 0.35 (−0.04 to 0.74) | ||
| RCR-F | |||
CII=complex 2, FCCP=carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone, MAX=FCCP-linked respiration, OXPHOS=oxidative phosphorylation capacity, RCR=respiratory control ratio. Bold type = p-value ≤ 0.05.
Respiration is measured as oxygen consumption rate (pmol/min/mg protein [platelets], pmol/min/mg dry weight [permeabilized fibers], pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]).
Reserve capacity is calculated as the difference between MAX and Basal respiration.
RCRs are calculated as ADP-stimulated State 3 respiration divided by oligomycin-linked respiration (RCR-A) and by MAX respiration divided by oligomycin-linked respiration (RCR-F).
In permeabilized muscle fiber preparations, basal respiration was measured with no added substrates, leak was measured with malate added, complex I OXPHOS capacity was measured using pyruvate, glutamate, and malate with a saturating amount of ADP. Complex I+II OXPHOS capacity was measured using complex I substrates with succinate added. MAX respiration was measured using complex I+II substrates with FCCP titrations added. Non-mitochondrial respiration was measured with MAX substrates with antimycin-A and rotenone substrates added.
In isolated mitochondrial preparations, CII respiration was measured using succinate and rotenone as substrates and using ADP, oligomycin, and FCCP injections to measure State 3, oligomycin, and MAX respiration, respectively.
N=16–17.
Fig. 3Associations among platelet bioenergetic parameters with skeletal and cardiac muscle bioenergetics. Regressions between platelet maximal uncoupled respiration and reserve capacity with respiratory control ratio and maximal uncoupled respiration from isolated mitochondria from skeletal and cardiac muscle as well as maximal oxidative phosphorylation capacity and maximal uncoupled respiration from permeabilized skeletal muscle fibers. Pearson's correlations and p-values for each association are shown.
Partial correlations between monocyte and platelet bioenergetics with permeabilized skeletal muscle bioenergetics. Partial correlations and 95% confidence intervals of monocyte and platelet respiratory parameters with bioenergetics from permeabilized skeletal muscle fibers left vastus lateralis, controlling for age, weight, and insulin status.
| Basal | −0.49 (−0.82 to 0.03) | −0.36 (−0.79 to 0.42) | −0.38 (−0.78 to 0.22) | −0.50 (−0.83 to 0.12) | −0.43 (−0.76 to 0.30) | ||||
| Complex I OXPHOS | 0.56 (−0.11 to 0.90) | 0.63 (−0.03 to 0.91) | 0.61 (−0.15 to 0.91) | ||||||
| Complex I+II OXPHOS | 0.52 (−0.30 to 0.95) | 0.79 (−0.30 to 0.97) | 0.75 (−0.28 to 0.98) | 0.57 (−0.42 to 0.93) | 0.57 (−0.03 to 0.91) | ||||
| MAX | −0.19 (−0.72 to 0.56) | −0.27 (−0.77 to 0.52) | −0.37 (−0.81 to 0.40) | 0.21 (−0.63 to 0.86) | 0.12 (−0.85 to 0.69) | −0.07 (−0.77 to 0.66) | 0.06 (−0.57 to 0.76) | −0.05 (−0.64−0.68) | −0.25 (−0.81−0.47) |
| Basal | −0.25 (−0.72 to 0.34) | −0.04 (−0.59 to 0.51) | 0.21 (−0.40 to 0.69) | −0.07 (−0.71 to 0.32) | 0.07 (−0.58 to 0.47) | 0.25 (−0.40 to 0.63) | −0.11 (−0.51 to 0.35) | 0.06 (−0.42 to 0.48) | 0.25 (−0.43 to 0.70) |
| Complex I OXPHOS | 0.18 (−0.40 to 0.69) | 0.34 (−0.22 to 0.78) | 0.08 (−0.14 to 0.79) | 0.19 (−0.39 to 0.60) | 0.34 (−0.20 to 0.66) | 0.46 (−0.09 to 0.79) | 0.14 (−0.48 to 0.60) | 0.30 (−0.27 to 0.65) | 0.43 (−0.15 to 0.74) |
| Complex I+II OXPHOS | 0.34 (−0.16 to 0.83) | 0.52 (−0.11 to 0.84) | 0.34 (−0.27 to 0.81) | 0.52 (0.11–0.78) | 0.31 (−0.31 to 0.79) | 0.50 (0.01–0.79) | |||
| MAX | 0.17 (−0.36 to 0.68) | 0.40 (−0.05 to 0.76) | 0.25 (−0.36 to 0.67) | 0.43 (−0.05 to 0.73) | 0.25 (−0.29 to 0.67) | 0.46 (−0.02 to 0.75) | |||
FCCP=carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone, HOMA-IR=homeostatic model of insulin resistance, MAX=FCCP-linked respiration, OXPHOS=oxidative phosphorylation capacity. Bold type = p-value ≤ 0.05.
Respiration is measured as oxygen consumption rate (pmol/min/mg protein [platelets], pmol/min/250,000 cells [monocytes], and pmol/min/mg dry weight [permeabilized fibers]).
Reserve capacity is calculated as the difference between MAX and Basal respiration.
In permeabilized muscle fiber preparations, basal respiration was measured with no added substrates, leak was measured with malate added, complex I OXPHOS capacity was measured using pyruvate, glutamate, and malate with a saturating amount of ADP. Complex I+II OXPHOS capacity was measured using complex I substrates with succinate added. MAX respiration was measured using complex I+II substrates with FCCP titrations added. Non-mitochondrial respiration was measured with MAX with antimycin-A and rotenone substrates added.
Monocytes: N=12. Platelets: N=17.
Partial correlations between monocyte bioenergetics with skeletal and cardiac muscle bioenergetics. Partial correlations and 95% confidence intervals of monocyte respiratory parameters with bioenergetics from isolated mitochondria from left vastus lateralis and cardiac tissue, controlling for age, weight, and insulin status.
| State 3 | −0.45 (−0.94 to 0.85) | −0.43 (−0.94 to 0.92) | −0.34 (−0.94 to 0.85) | −0.19 (−0.81 to 0.29) | −0.19 (−0.80 to 0.22) | −0.17 (−0.74 to 0.15) | −0.37 (−0.87 to 0.68) | −0.39 (−0.87 to 0.59) | −0.39 (−0.91 to 0.54) |
| MAX | −0.22 (−0.90 to 0.90) | −0.19 (−0.87 to 0.93) | −0.13 (−0.88 to 0.92) | −0.18 (−0.78 to 0.37) | −0.16 (−0.76 to 0.26) | −0.11 (−0.68 to 0.24) | −0.37 (−0.88 to 0.71) | −0.37 (−0.91 to 0.76) | −0.33 (−0.95 to 0.74) |
| RCR-A | 0.67 (−0.11 to 0.98) | ||||||||
| RCR-F | 0.61 (−0.15 to 0.95) | 0.58 (−0.25 to 0.84) | 0.73 (−0.36 to 0.99) | 0.71 (−0.15 to 0.99) | |||||
| State 3 | 0.06 (−0.55 to 0.80) | 0.10 (−0.55 to 0.74) | 0.14 (−0.63 to 0.69) | 0.13 (−0.42 to 0.82) | 0.18 (−0.47 to 0.89) | 0.26 (−0.51 to 0.82) | 0.11 (−0.47 to 0.76) | 0.16 (−0.50 to 0.82) | 0.22 (−0.67 to 0.85) |
| MAX | 0.17 (−0.44 to 0.90) | 0.20 (−0.43 to 0.87) | 0.22 (−0.50 to 0.81) | 0.22 (−0.34 to 0.83) | 0.26 (−0.46 to 0.88) | 0.31 (−0.60 to 0.89) | 0.24 (−0.26 to 0.78) | 0.29 (−0.35 to 0.85) | 0.33 (−0.61 to 0.90) |
| RCR-A | 0.32 (−0.40 to 0.90) | 0.42 (−0.32 to 0.91) | 0.53 (−0.05 to 0.87) | 0.53 (−0.33 to 0.91) | 0.61 (−0.10 to 0.94) | 0.45 (−0.27 to 0.93) | 0.51 (−0.18 to 0.98) | 0.54 (−0.53 to 0.99) | |
| RCR-F | 0.36 (−0.77−0.93) | 0.36 (−0.78 to 0.94) | 0.33 (−0.77 to 0.92) | 0.57 (−0.44 to 0.96) | 0.57 (−0.51 to 0.97) | 0.48 (−0.39 to 0.95) | 0.52 (−0.01 to 0.96) | 0.51 (−0.26 to 0.97) | 0.42 (−0.37 to 0.92) |
CII=complex 2, FCCP=carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone, HOMA-IR=homeostatic model of insulin resistance, MAX=FCCP-linked respiration, OXPHOS=oxidative phosphorylation capacity, RCR=respiratory control ratio. Bold type = p-value ≤ 0.05.
Respiration is measured as oxygen consumption rate (pmol/min/250,000 cells [monocytes] and pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]).
Reserve capacity is calculated as the difference between MAX and Basal respiration.
RCRs are calculated as ADP-stimulated State 3 respiration divided by oligomycin-linked respiration (RCR-A) and by MAX respiration divided by oligomycin-linked respiration (RCR-F).
In isolated mitochondrial preparations, CII respiration was measured using succinate and rotenone as substrates and using ADP, oligomycin, and FCCP injections to measure State 3, oligomycin, and MAX respiration, respectively.
N=11–12.
Partial correlations between platelet bioenergetics with skeletal and cardiac muscle bioenergetics. Partial correlations and 95% confidence intervals of platelet respiratory parameters with bioenergetics from isolated mitochondria from left vastus lateralis and cardiac tissue, controlling for age, weight, and insulin status.
| State 3 | 0.05 (−0.52 to 0.67) | 0.34 (−0.02 to 0.69) | 0.03 (−0.68 to 0.55) | 0.30 (−0.32 to 0.62) | −0.02 (−0.54 to 0.59) | 0.28 (−0.13 to 0.66) | |||
| MAX | 0.26 (−0.32 to 0.75) | 0.51 (0.11–0.81) | 0.10 (−0.61 to 0.59) | 0.35 (−0.24 to 0.67) | 0.02 (−0.52 to 0.62) | 0.30 (−0.18 to 0.74) | |||
| RCR-A | 0.23 (−0.27 to 0.83) | 0.43 (−0.19 to 0.85) | 0.29 (−0.31 to 0.84) | 0.51 (−0.05 to 0.84) | |||||
| RCR-F | 0.56 (0.08–0.93) | 0.50 (−0.09 to 0.93) | 0.36 (−0.25 to 0.91) | ||||||
| State 3 | −0.27 (−0.68 to 0.28) | −0.05 (−0.53 to 0.44) | 0.21 (−0.25 to 0.65) | −0.26 (−0.60 to 0.11) | −0.08 (−0.46 to 0.31) | 0.18 (−0.21 to 0.53) | −0.24 (−0.70 to 0.40) | −0.04 (−0.58 to 0.54) | 0.23 (−0.30 to 0.70) |
| MAX | −0.13 (−0.61 to 042) | 0.06 (−0.48 to 0.55) | 0.26 (−0.23 to 067) | −0.16 (−0.53 to 0.21) | 0.01 (−0.41 to 0.37) | 0.22 (−0.21 to 0.58) | −0.10 (−0.60 to 0.40) | 0.08 (−0.48 to 0.55) | 0.30 (−0.24 to 0.71) |
| RCR-A | 0.16 (−0.49 to 0.60) | 0.29 (−0.41 to 0.71) | 0.34 (−0.28 to 0.77) | 0.35 (−0.16 to 0.71) | 0.43 (−0.13 to 0.84) | 0.29 (−0.36 to 0.74) | 0.37 (−0.27 to 0.84) | 0.37 (−0.15 to 0.79) | |
| RCR-F | 0.46 (−0.01 to 0.78) | 0.49 (−0.02 to 0.80) | 0.39 (−0.10 to 0.73) | 0.56 (−0.10 to 0.90) | 0.58 (−0.09 to 0.87) | 0.46 (−0.07 to 0.80) | |||
CII=complex 2, FCCP=carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone, HOMA-IR=homeostatic model of insulin resistance, MAX=FCCP-linked respiration, OXPHOS=oxidative phosphorylation capacity, RCR=respiratory control ratio. Bold type = p-value ≤ 0.05.
Respiration is measured as oxygen consumption rate (pmol/min/mg protein [platelets] and pmol/min/5 µg mitochondrial protein [left vastus and cardiac tissues]).
Reserve capacity is calculated as the difference between MAX and Basal respiration.
RCRs are calculated as ADP-stimulated State 3 respiration divided by oligomycin-linked respiration (RCR-A) and by MAX respiration divided by oligomycin-linked respiration (RCR-F).
In isolated mitochondrial preparations, CII respiration was measured using succinate and rotenone as substrates and using ADP, oligomycin, and FCCP injections to measure State 3, oligomycin, and MAX respiration, respectively.
N=16.